Our DPX® technology could help us create a new class of immunotherapies that generate targeted, long-lasting immune activation with potentially fewer side effects. is a clinical-stage immuno-oncology pharmaceutical company with the potential to make history by developing a first-in-class effective T cell-targeted immune therapy for cancer. We have built an unprecedented delivery platform called DP
X® with a differentiated mechanism of action that generates targeted immune cells directly into the human body, which produces robust and sustained capabilities to destroy cancer cells. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides of survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers.
